Charles River Laboratories Reports Mixed Q1 2026 Results Amid Strategic Divestitures
Event summary
- Charles River Laboratories reported Q1 2026 revenue of $995.8 million, up 1.2% year-over-year, but organic revenue declined 1.5%.
- GAAP operating margin improved to 12.0% from 7.6%, driven by lower amortization expenses, but non-GAAP operating margin decreased to 16.3% from 19.1%.
- The company completed the divestiture of its CDMO and Cell Solutions businesses to GI Partners on May 6, 2026.
- Charles River repurchased 1.1 million shares for $200.0 million in Q1 2026, with $800.0 million remaining under its stock repurchase authorization.
- The company reaffirmed its 2026 organic revenue and non-GAAP earnings per share guidance but reduced its reported revenue outlook by 50 basis points due to foreign exchange rate changes.
The big picture
Charles River Laboratories' Q1 2026 results reflect a mixed performance, with improvements in GAAP operating margin offset by declines in organic revenue and non-GAAP operating margin. The completion of strategic divestitures aims to refine the company's portfolio and focus on core competencies. The company's ability to navigate market conditions and sustain growth in key segments will be critical in the coming quarters.
What we're watching
- Segment Performance
- How the decline in organic revenue in the RMS and DSA segments will impact overall growth and whether the Manufacturing Solutions segment can sustain its momentum.
- Divestiture Impact
- The pace at which the completed divestitures will enable Charles River to focus on core competencies and drive synergistic growth.
- Market Conditions
- Whether the company can mitigate the impact of foreign exchange rate changes and other market conditions on its reported revenue outlook.
Related topics